000			04037nam a22003015i 4500
001			402933
003			ES-MaUEC
005			20240528105943.0
007			cr nn 008mamaa
008			240117s2023 sz | o |||| 0|eng d
020			_a9783031473319
024	7		_a10.1007/978-3-031-47331-9 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aQR46 _b2023 EB
245	0	0	_aHelicobacter pylori and Gastric Cancer _cedited by Steffen Backert
250			_a1st ed. 2023
264		1	_aCham _bSpringer International Publishing _c2023
300			_a1 recurso en línea
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aCurrent Topics in Microbiology and Immunology _x2196-9965 ; _v444
505	0		_aGastric stem cell biology and Helicobacter pylori infection -- Clinical pathogenesis and molecular mechanisms of gastric cancerogenesis -- Helicobacter pylori metabolism and mitochondrial dysfunction in gastric cancer development -- Immune biology and persistence of Helicobacter pylori in gastric diseases -- Pathogenomics of Helicobacter pylori infection -- Helicobacter pylori interactions with the microbiota and gastric cancer development -- Helicobacter pylori-induced host cell DNA damage and gastric carcinogenesis -- Gastric inflammation and oncogenic signal transduction networks by Helicobacter pylori -- Impact of Helicobacter pylori oncoprotein CagA and vacuolating cytotoxin VacA in gastric cancer -- Role of proteases in Helicobacter pylori infections and gastric diseases -- Clinical management of gastric cancer treatment regimes.
520			_aThis volume explores in detail the molecular biology, genetics and immunology of the bacterium Helicobacter pylori that causes serious gastric diseases such as gastric cancer. The book provides in-depth insights into the mechanisms of H. pylori-induced pathogenicity, gives an overview of how the bacterium colonizes the human gut, how it manages to persist in the body and which factors play a role in the development of H. pylori-induced gastric cancer. Furthermore, the interaction between the Gram-negative bacterium and the human gut microbiome is explored, and clinical management and treatment strategies to combat gastric cancer are discussed. Helicobacter pylori is an extremely successful pathogen that persistently colonizes the gut of about 50% of the world's population. H. pylori and its human host share a long co-evolutionary relationship that dates back for at least last 100,000 years and possibly longer. Infection by this bacterium is a high-risk factor for the development of gastric diseases, including gastric cancer. Gastric cancer is associated with high morbidity and mortality and represents the 5th most common malignant tumour and the 4th leading cause of cancer-related death worldwide. H. pylori is the first bacterium that has been classified as a type-I carcinogen by the International Agency for Research on Cancer (IARC). Recent research progress identified crucial bacterial, host and environmental factors which control H. pylori-induced gastric malignancy. New studies also suggest that specific human germline mutations and other genetic aberrations have an important impact on H. pylori-induced pathology. In this volume, all these recently discovered mechanisms are reviewed in the light of gastric cancer development, and H. pylori epidemiology, virulence factors, immune evasion, pathophysiology, cancer signalling and novel therapeutic protocols are presented. This volume is aimed at researchers in the fields of immunology, genetics, microbiology and medicine who are interested in the detailed mechanisms of the pathogenicity of this carcinogenic stomach bacterium.
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-031-47331-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
988			_aSpringer_Medicine_2023
999			_c402933 _d402933